Table 1. Anti-HBs antibody seroprotection rates and geometric mean concentrations post-primary vaccination (unboosted at year 5) at infancy until year 20 (LT-ATP cohort for immunogenicity).

Time-Point (year)	N	S+		≥ 10 mIU/ml		GMC mIU/ml
		%	95% CI [LL-UL]	%	95% CI [LL-UL]	Value	95% CI [LL-UL]
Post-primary	54	100	[93.4–100]	100	[93.4–100]	4436.3	[3084.7–6380.0]
2	48	100	[92.6–100]	100	[92.6–100]	489.1	[301.9–792.3]
3	43	100	[91.8–100]	97.7	[87.7–99.9]	248.5	[158.9–388.8]
4	40	100	[91.2–100]	100	[91.2–100]	235.8	[158.0–352.0]
5	32	100	[89.1–100]	100	[89.1–100]	185.5	[113.9–302.1]
6	36	97.2	[85.5–99.9]	94.4	[81.3–99.3]	120.1	[75.5–191.0]
7	34	100	[89.7–100]	100	[89.7–100]	127.2	[83.5–193.9]
8	34	100	[89.7–100]	94.1	[80.3–99.3]	104.8	[60.1–182.9]
9	32	100	[89.1–100]	93.8	[79.2–99.2]	90.9	[52.2–158.4]
10	13	100	[75.3–100]	92.3	[64.0–99.8]	68.2	[30.3–153.2]
11	20	100	[83.2–100]	95.0	[75.1–99.9]	64.4	[27.9–148.8]
12	31	100	[88.8–100]	83.9	[66.3–94.5]	54.7	[30.7–97.5]
13	30	96.7	[82.8–99.9]	86.7	[69.3–96.2]	74.1	[41.0–134.1]
14	24	87.5	[67.6–97.3]	70.8	[48.9–87.4]	51.4	[23.9–110.5]
15	21	71.4	[47.8–88.7]	66.7	[43.0–85.4]	46.9	[23.5–93.5]
16	25	88.0	[68.8–97.5]	68.0	[46.5–85.1]	44.4	[22.7–86.7]
17	24	87.5	[67.6–97.3]	66.7	[44.7–84.4]	37.8	[18.8–76.0]
18	22	90.9	[70.8–98.9]	68.2	[45.1–86.1]	35.2	[18.9–65.7]
19	22	86.4	[65.1–97.1]	63.6	[40.7–82.8]	29.7	[14.8–59.5]
20	25	92.0	[74.0–99.0]	64.0	[42.5–82.0]	20.4	[12.1–34.2]

N, number of subjects with available results; S+, seropositivity defined as anti-HBs antibody concentrations ≥1.0 mIU/ml up to year 12 and ≥3.3 mIU/ml from year 13 onwards; GMC, geometric mean concentrations calculated on seropositive subjects; %, number/percentage of seropositive subjects or subjects with anti-HBs antibody concentrations ≥10 mIU/ml; 95% CI, exact 95% confidence interval; LL, lower limit of 95% confidence interval; UL, upper limit of 95% confidence interval; post-primary, anti-HBs antibody seroprotection rates and GMCs at Month 13, following primary vaccination at months 0, 1, 2 and 12.